Direkt zum Inhalt
Merck
Alle Fotos(2)

Key Documents

View All Documentation

S0758

Sigma-Aldrich

Sulfaphenazole

≥98%

Synonym(e):

4-Amino-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(2)

About This Item

Empirische Formel (Hill-System):
C15H14N4O2S
CAS-Nummer:
526-08-9
Molekulargewicht:
314.36
EG-Nummer:
208-384-3
MDL-Nummer:
MFCD00057226
UNSPSC-Code:
12352204
PubChem Substanz-ID:
24278198
NACRES:
NA.77

Qualitätsniveau

100

Assay

≥98%

Form

powder

Löslichkeit

ethanol: 25 mg/mL, clear, colorless to yellow

Lagertemp.

2-8°C

SMILES String

Nc1ccc(cc1)S(=O)(=O)Nc2ccnn2-c3ccccc3

InChI

1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2

InChIKey

QWCJHSGMANYXCW-UHFFFAOYSA-N

Angaben zum Gen

human ... CYP2C18(1562) , CYP2C19(1557) , CYP2C9(1559)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Anwendung

Sulfaphenazole has been used as a positive control to inhibit cytochrome P450 2C9 (cyp2c9) to quantify Rhodiola rosea inhibition. It has also been used as cytochrome P450 2C9 (cyp2c9) inhibitor in endothelial cells and microsomal preparations.

Biochem./physiol. Wirkung

Antibacterial. Specific inhibitor of CYP2C9. Blocks pro-inflammatory and atherogenic effects of linoleic acid (increase in oxidative stress and activation of AP-1) mediated by CYP2C9. Specific inhibitor of CYP2C9. Blocks pro-inflammatory and atherogenic effects of linoleic acid (increase in oxidative stress and activation of AP-1) mediated by CYP2C9. Inhibits bradykinin-induced tPA release.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Gloves, type N95 (US)

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 6

1 of 6

vibrant-m

M6311

Greiner FLUOTRAC™ 200 384 well plates

4-Hydroxymephenytoin

Sigma-Aldrich

UC126

4-Hydroxymephenytoin

USP

USP

1446859

Montelukast Natrium

Tienilic Acid ≥98% (HPLC)

Sigma-Aldrich

SML0505

Tienilic Acid

Sulfamonomethoxin

Sigma-Aldrich

S0508

Sulfamonomethoxin

Chinidin crystallized, ≥98.0% (dried material, NT)

Sigma-Aldrich

22600

Chinidin

Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform
Moraes CB, et al.
SLAS discovery, 24(3), 346-361 (2019)
Ralf Heim et al.
Journal of medicinal chemistry, 51(16), 5064-5074 (2008-08-05)
Recently, we reported on the development of potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. A major drawback of these nonsteroidal compounds was a strong inhibition of the hepatic drug-metabolizing
Simon Lucas et al.
Journal of medicinal chemistry, 54(7), 2307-2319 (2011-03-10)
Pyridine substituted 3,4-dihydro-1H-quinolin-2-ones (e.g., 1-3) constitute a class of highly potent and selective inhibitors of aldosterone synthase (CYP11B2), a promising target for the treatment of hyperaldosteronism, congestive heart failure, and myocardial fibrosis. Among these, ethyl-substituted 3 possesses high selectivity against
Vienna E Brunt et al.
The Journal of physiology, 590(15), 3523-3534 (2012-06-08)
While it is accepted that NO is responsible for ∼60% of the plateau in cutaneous thermal hyperaemia, a large portion of the response remains unknown. We sought to determine whether the remaining ∼40% could be attributed to EDHF-mediated activation of
Zhiping Jin et al.
Basic & clinical pharmacology & toxicology, 130(5), 592-605 (2022-03-16)
Anlotinib is a small molecule of novel tyrosine kinase inhibitor initially approved to treat non-small cell lung cancer in China. Drug-drug interaction (DDI) is an extrinsic factor important for the appropriate use of anlotinib in clinical practice. In vitro experiments
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.